StoneX Group’s Arcadia Biosciences RKDA Stock Holding History

StoneX Group’s Portfolio RKDA Stock Details RKDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-329	Closed	-$13.1K	–	480
2022 Q2	$13.1K	Buy	+329	New	+$15.1K	﹤0.01%	451

Other funds holding RKDA

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

StoneX Group's RKDA Position: Q3 2022 in Review

StoneX Group sold out of Arcadia Biosciences (RKDA) in Q3 2022, closing a stake of 329 shares — an estimated $13.1K sold.

StoneX Group first reported a position in RKDA in Q2 2022 and held it in 1 quarter. The position peaked at $13.1K in Q2 2022. 24 funds tracked by Wall St. Rank hold RKDA as of Q3 2022.

StoneX Group reported no remaining Arcadia Biosciences position as of Q3 2022 after selling out during the quarter.
StoneX Group sold 329 Arcadia Biosciences shares in Q3 2022, an estimated $13.1K.
StoneX Group first reported a position in Arcadia Biosciences in Q2 2022 and held it in 1 quarter.
StoneX Group's Arcadia Biosciences position peaked at $13.1K in Q2 2022.
24 funds tracked by Wall St. Rank held Arcadia Biosciences as of Q3 2022.

Based on StoneX Group's 13F filing for Q3 2022, filed 8 Nov 2022.